AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

AbelZeta Pharma, Inc. announced the acceptance of an abstract related to the clinical study of C-CAR031, a CAR-T therapy for hepatocellular carcinoma, at the 2024 ASCO Annual Meeting. The therapy is developed in collaboration with AstraZeneca and will be presented in June 2024.

Positive

• AbelZeta Pharma, Inc. announced the acceptance of an abstract for C-CAR031 at the 2024 ASCO Annual Meeting.
• C-CAR031 is an autologous, armored GPC3-targeting CAR-T therapy for hepatocellular carcinoma.
• The therapy is based on AstraZeneca's novel GPC3-targeting CAR-T design using their TGFβRII dominant negative armoring discovery platform.
• C-CAR031 is being developed under a co-development agreement between AbelZeta and AstraZeneca.
• The oral presentation of the abstract is scheduled for June 3, 2024, at the ASCO Annual Meeting in Chicago.

Negative

• None.

ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 to June 4, 2024. C-CAR031 is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta receptor II (TGFβRII) dominant negative armoring discovery platform and is manufactured by AbelZeta in China. C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca.¹

Details of the oral presentation are as follows:

Abstract Title: "Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)."
Abstract Number: 4019
Session Type and Title: Rapid Oral Abstract – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: 6/3/2024; 9:45 AM-11:15 AM CDT

About AbelZeta Pharma, Inc.
AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

Forward-Looking Statements
Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Company Contact:
Sarah Kelly
Director of Communications
AbelZeta Pharma, Inc.
+1 (240) 552 5870
sarah.kelly@abelzeta.com
www.abelzeta.com

References

1. AbelZeta. AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China. December 2023. https://www.abelzeta.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting-302127271.html

SOURCE AbelZeta Pharma, Inc.

FAQ

What did AbelZeta announce regarding C-CAR031?

AbelZeta announced the acceptance of an abstract related to the clinical study of C-CAR031 for oral presentation at the 2024 ASCO Annual Meeting.

What type of therapy is C-CAR031?

C-CAR031 is an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy.

Who designed the novel GPC3-targeting CAR-T for C-CAR031?

AstraZeneca designed the novel GPC3-targeting CAR-T for C-CAR031 using their TGFβRII dominant negative armoring discovery platform.

Where is C-CAR031 being manufactured?

C-CAR031 is being manufactured by AbelZeta in China.

When and where will the oral presentation of the abstract take place?

The oral presentation of the abstract is scheduled for June 3, 2024, at the ASCO Annual Meeting in Chicago.